Arch Biopartners (TSE:ARCH)
:ARCH
ARCH Stock Chart & Stats
C$1.37
-C$0.06(-3.14%)
At close: 4:00 PM EST
C$1.37
-C$0.06(-3.14%)
Day’s Range― - ―
52-Week RangeC$0.46 - C$1.95
Previous CloseN/A
Volume5.12K
Average Volume (3M)43.97K
Market Cap
C$39.49M
Enterprise ValueC$42.12M
Total Cash (Recent Filing)C$4.16K
Total Debt (Recent Filing)C$2.63M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding66,933,290
10 Day Avg. Volume31,059
30 Day Avg. Volume43,967
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)-21.63
Price to Sales (P/S)0.00
P/FCF Ratio-53.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Therapeutic PlatformA platform focus (DPEP-1 inhibitor plus LSALT/Metablok and antibody programs) creates reusable R&D assets and scientific continuity. This structural approach raises the odds of translating one program into partnered development or multiple indications over months to years, appealing to collaborators.
Program DiversificationHaving both a peptide program and a monoclonal antibody targeting different biology reduces binary risk. Diversified development candidates improve overall portfolio success probability and give management more strategic options for partnering, licensing, or prioritizing resources long term.
Clear Monetization Model Via PartnershipsA partnering/out‑licensing business model is a durable commercialization route for clinical‑stage biotech. It limits near‑term capital needs, aligns incentives with larger pharma, and provides defined streams (upfronts, milestones, royalties) as structural pathways to revenue once programs progress.
Bears Say
Negative Equity And Tiny Asset BasePersistently negative equity and an extremely small asset base constrain financial flexibility and raise counterparty concerns. Over a multi‑month horizon this increases dependency on external funding, limits credit options, and heightens dilution risk when raising capital.
Sustained Cash BurnConsistent negative operating and free cash flow indicates ongoing funding needs to sustain R&D and trials. Absent material cost changes or partner funding, this structural cash burn implies recurring financings or deals will be required, pressuring management and potential dilution.
No Current Revenue; Recurring LossesZero trailing revenue and repeated net losses reflect a non‑commercial stage business dependent on milestones or financings. Over the medium term this limits internal funding sources, increases execution risk for trials, and can weaken negotiating leverage with potential partners.
Arch Biopartners News
ARCH FAQ
What was Arch Biopartners’s price range in the past 12 months?
Arch Biopartners lowest stock price was C$0.46 and its highest was C$1.95 in the past 12 months.
What is Arch Biopartners’s market cap?
Arch Biopartners’s market cap is C$39.49M.
When is Arch Biopartners’s upcoming earnings report date?
Arch Biopartners’s upcoming earnings report date is Jun 02, 2026 which is in 60 days.
How were Arch Biopartners’s earnings last quarter?
Currently, no data Available
Is Arch Biopartners overvalued?
According to Wall Street analysts Arch Biopartners’s price is currently Overvalued.
Does Arch Biopartners pay dividends?
Arch Biopartners does not currently pay dividends.
What is Arch Biopartners’s EPS estimate?
Arch Biopartners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Biopartners have?
Arch Biopartners has 66,933,290 shares outstanding.
What happened to Arch Biopartners’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arch Biopartners?
Currently, no hedge funds are holding shares in TSE:ARCH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arch Biopartners Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.44%
12-Months-Change
Fundamentals
Return on Equity
72.34%
Trailing 12-Months
Asset Growth
-95.31%
Trailing 12-Months
Company Description
Arch Biopartners
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.
Technical Analysis
Satellos Bioscience
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---